---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-25-000007"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:12:34.967151+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY

## Summary
- Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.
- Full-year net income $1.195B ($24.64 diluted EPS) vs $984.8M in 2023 (diluted EPS $19.81).
- Tyvaso franchise revenue grew 31% to $1.62B in 2024, driven by Tyvaso DPI (up 41%).
- Completed $1B accelerated share repurchase, repurchasing ~3.55M shares.
- Recorded $71.1M litigation accrual for Sandoz; R&D expense up 18% on organ projects.

## SEC filing metadata
- accession: 0001082554-25-000007
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/0001082554-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255425000007/uthr-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-25-000007
- JSON: https://secwatch.observer/filing/0001082554-25-000007.json
- Plain text: https://secwatch.observer/filing/0001082554-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.